omaveloxolone Friedreich
Selected indexed studies
- Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). (Ann Neurol, 2021) [PMID:33068037]
- Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension. (Mov Disord, 2023) [PMID:36444905]
- Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. (Ann Clin Transl Neurol, 2024) [PMID:37691319]
_Worker-drafted node — pending editorial review._
Connections
omaveloxolone Friedreich is a side effect of
Sources
- Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). (2021) pubmed
- Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension. (2023) pubmed
- Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. (2024) pubmed
- Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. (2019) pubmed
- Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations. (2024) pubmed
- Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. (2024) pubmed
- Omaveloxolone: First Approval. (2023) pubmed
- Friedreich's ataxia-a rare multisystem disease. (2025) pubmed
- Safety and efficacy of omaveloxolone v/s placebo for the treatment of Friedreich's ataxia in patients aged more than 16 years: a systematic review. (2024) pubmed
- Approval of omaveloxolone for Friedreich ataxia. (2024) pubmed